September 27, 2023

Long-Term Effects of Ranitidine on Cancer Development

Several years ago, the FDA asked manufacturers to remove products containing ranitidine from the U.S. market, pointing to potential cancer risks related to a known human carcinogen that was an ingredient in many of them. Now, a new study has identified no difference in cancer risk for patients who used ranitidine compared with other histamine-2 receptor antagonists. Read more.

Advertisement

Semaglutide Reduces Symptom Burden in HFpEF

Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in the obese. Yet, no specific therapies have been approved to treat it. Find out why a new study suggests that therapy with semaglutide, originally approved for type 2 diabetes treatment, might be valuable for patients with HFpEF.

Bridge Program Provides Free COVID-19 Shots for Uninsured

New COVID-19 booster vaccines have been recommended just as cases of SARS-CoV-2 infections and hospitalizations are continuing to rise across the United States. Find out how the Bridge Access program works and how it might lead to a more permanent program for adults who are uninsured or only partly insured for COVID-19 and therapeutics.

Advertisement

Increasing Therapeutic Errors Among Pediatric ADHD Medications

There has been a substantial increase in the number of therapeutic errors related to attention-deficit/hyperactivity disorder (ADHD) medications serious enough to be reported to poison control centers—partly because so many more adolescents and children have been diagnosed over the past 2 decades. Errors have increased in both out-of-hospital and inpatient settings, according to a new report published in Pediatrics. Read more.

 
Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
AdvertisementAdvertisement